- Home
- INMB vs ATYR Comparison
INMB vs ATYR Comparison
Compare INMB & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INMB | ATYR |
|---|---|---|
| Founded | 2015 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 64.7M | 49.2M |
| IPO Year | 2018 | 2015 |
Fundamental Metrics
Financial Performance| Metric | INMB | ATYR |
|---|---|---|
| Price | $2.32 | $0.36 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 5 | 9 |
| Target Price | ★ $5.40 | $3.67 |
| AVG Volume (30 Days) | 327.1K | ★ 728.9K |
| Earning Date | 05-07-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 11.85 | 6.98 |
| EPS | N/A | ★ N/A |
| Revenue | $50,000.00 | ★ $190,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 257.14 | N/A |
| 52 Week Low | $1.09 | $0.37 |
| 52 Week High | $2.60 | $1.12 |
Technical Indicators
Market Signals| Indicator | INMB | ATYR |
|---|---|---|
| Relative Strength Index (RSI) | 54.39 | 25.85 |
| Support Level | $2.21 | N/A |
| Resistance Level | $2.55 | $0.59 |
| Average True Range (ATR) | 0.15 | 0.03 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 58.27 | 2.13 |
Price Performance
Historical ComparisonAbout INMB INmune Bio Inc.
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.
About ATYR aTyr Pharma Inc.
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).